Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 5

MeCP2 in the regulation of neural activity: Rett syndrome pathophysiological perspectives

Authors Cuddapah V, Nwaobi S, Percy A, Olsen M

Received 28 May 2015

Accepted for publication 30 July 2015

Published 14 October 2015 Volume 2015:5 Pages 103—116

DOI https://doi.org/10.2147/DNND.S61269

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Mafalda Cacciottolo

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Thomas Müller


Vishnu Anand Cuddapah,1,* Sinifunanya Elvee Nwaobi,1,* Alan K Percy,2 Michelle Lynne Olsen1

1Department of Cell, Developmental, and Integrative Biology, 2Civitan International Research Center, University of Alabama at Birmingham, Birmingham, AL, USA

*These authors contributed equally to this work

Abstract: Rett syndrome (RTT), an X-linked neurodevelopment disorder, occurs in approximately one out of 10,000 females. Individuals afflicted by RTT display a constellation of signs and symptoms, affecting nearly every organ system. Most striking are the neurological manifestations, including regression of language and motor skills, increased seizure activity, autonomic dysfunction, and aberrant regulation of breathing patterns. The majority of girls with RTT have mutations in the gene encoding for methyl-CpG binding protein 2 (MeCP2). Since the discovery of this genetic cause of RTT in 1999, there has been an accelerated pace of research seeking to understand the role of MeCP2 in the brain in the hope of developing a disease-modifying therapy for RTT. In this study, we review the clinical features of RTT and then explore the latest mechanistic studies in order to explain how a mutation in MeCP2 leads to these unique features. We cover in detail studies examining the role of MeCP2 in neuronal physiology, as well as recent evidence that implicates a key role for glia in the pathogenesis of RTT. In the past 20 years, these basic and clinical studies have yielded an extraordinary understanding of RTT; as such, we end this narrative review considering the translation of these studies into clinical trials for the treatment of RTT.

Keywords: MeCP2, epigenetic regulation, Rett syndrome, neurons, glia, astrocyte, oligodendrocyte, microglia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]